FILINGS
| AZN 0000901832 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2025-04-11 | 6-K | RESULT OF AGM | View Document |
| 2025-04-10 | SCHEDULE 13G/A | View Document | |
| 2025-04-04 | 6-K | IMFINZI APPROVED IN EU FOR AEGEAN | View Document |
| 2025-04-04 | 6-K | ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER | View Document |
| 2025-04-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-03-31 | 6-K | CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL | View Document |
| 2025-03-31 | 6-K | IMFINZI APPROVED IN THE US FOR BLADDER CANCER | View Document |
| 2025-03-21 | 6-K | AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING | View Document |
| 2025-03-17 | 6-K | ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 2025-03-17 | 6-K | IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC | View Document |
| 2025-03-17 | 6-K | ASTRAZENECA TO ACQUIRE ESOBIOTEC | View Document |
| 2025-03-12 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-03-07 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-03-07 | 6-K | NOTICE OF AGM | View Document |
| 2025-03-07 | 6-K | IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER | View Document |
| 2025-03-07 | 6-K | FORM 6-K | View Document |
| 2025-03-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-03-05 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-03-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-03-03 | 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN | View Document |
| 2025-02-28 | 6-K | ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER | View Document |
| 2025-02-26 | 6-K | CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER | View Document |
| 2025-02-19 | 6-K | FILING OF FORM 20-F WITH SEC | View Document |
| 2025-02-18 | IRANNOTICE | IRANNOTICE | View Document |
| 2025-02-18 | 20-F | FORM 20-F | View Document |
| 2025-02-18 | 6-K | FORM 6-K | View Document |
| 2025-02-18 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-02-18 | 6-K | ANNUAL FINANCIAL REPORT | View Document |
| 2025-02-18 | 6-K | DIRECTORATE CHANGE | View Document |
| 2025-02-06 | 6-K | FINAL RESULTS | View Document |
| 2025-02-05 | EFFECT | View Document | |
| 2025-02-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-02-03 | 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC | View Document |
| 2025-01-28 | 6-K | ENHERTU APPROVED IN US FOR BREAST CANCER POST ET | View Document |
| 2025-01-24 | SCHEDULE 13D/A | View Document | |
| 2025-01-21 | F-6 | View Document | |
| 2025-01-21 | 6-K | DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER | View Document |
| 2025-01-17 | 6-K | CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL | View Document |
| 2025-01-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-12-26 | 6-K | DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU | View Document |
| 2024-12-23 | 6-K | TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL | View Document |
| 2024-12-16 | 6-K | DIRECTORATE CHANGE | View Document |
| 2024-12-05 | 6-K | IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC | View Document |
| 2024-12-04 | 6-K | ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL | View Document |
| 2024-12-02 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2024-12-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-11-25 | 6-K | TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER | View Document |
| 2024-11-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-11-18 | 6-K | TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA | View Document |
| 2024-11-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-11-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-11-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-11-12 | 6-K | ASTRAZENECA INVESTS $3.5 BILLION IN US | View Document |
| 2024-11-12 | 6-K | KOMET PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 2024-11-12 | 6-K | 9M AND Q3 2024 RESULTS | View Document |
| 2024-11-12 | 6-K | DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN | View Document |
| 2024-11-08 | 6-K | TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS | View Document |
| 2024-11-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-10-30 | 6-K | AZN CHINA PRESIDENT UNDER INVESTIGATION | View Document |
| 2024-10-28 | SC 13G | SC 13G | View Document |
| 2024-10-21 | 6-K | FORM 6-K | View Document |
| 2024-10-11 | SC 13G | SC 13G | View Document |
| 2024-10-07 | 6-K | ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET | View Document |
| 2024-10-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-09-26 | 6-K | TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER | View Document |
| 2024-09-23 | 6-K | FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA | View Document |
| 2024-09-23 | 6-K | FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 | View Document |
| 2024-09-20 | 6-K | FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US | View Document |
| 2024-09-18 | 6-K | FASENRA EGPA US FDA APPROVAL | View Document |
| 2024-09-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-09-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-08-16 | 6-K | IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER | View Document |
| 2024-08-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-07-30 | 6-K | ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING | View Document |
| 2024-07-29 | 6-K | CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS | View Document |
| 2024-07-26 | 6-K | ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER | View Document |
| 2024-07-25 | 6-K | FORM 6K | View Document |
| 2024-07-15 | 6-K | ACQUISITION OF AMOLYT PHARMA COMPLETED | View Document |
| 2024-07-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-07-01 | 6-K | LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL | View Document |
| 2024-06-26 | 11-K | ANNUAL REPORT | View Document |
| 2024-06-25 | 6-K | UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL | View Document |
| 2024-06-25 | 6-K | IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER | View Document |
| 2024-06-18 | 6-K | UPDATE ON CAPITELLO-290 PHASE III TRIAL | View Document |
| 2024-06-17 | 6-K | IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER | View Document |
| 2024-06-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-06-04 | 6-K | FORM 6-K | View Document |
| 2024-06-04 | 25-NSE | View Document | |
| 2024-06-03 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2024-06-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-06-03 | 6-K | TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU | View Document |
| 2024-05-28 | 6-K | DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER | View Document |
| 2024-05-21 | 6-K | ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 | View Document |
| 2024-05-20 | 6-K | ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE | View Document |
| 2024-05-16 | 6-K | SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT | View Document |
| 2024-05-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-05-07 | 6-K | ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT | View Document |
| 2024-05-02 | 6-K | CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL | View Document |
| 2024-05-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-04-29 | 6-K | TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
